January 8, 2018 / 11:55 AM / 7 months ago

BRIEF-Merck's Keytruda Significantly Improved Recurrence-Free Survival Compared To Placebo As Adjuvant Therapy

Jan 8 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED RECURRENCE-FREE SURVIVAL COMPARED TO PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH STAGE 3 RESECTED HIGH-RISK MELANOMA (EORTC1325/KEYNOTE-054)

* MERCK & CO INC - PHASE 3 EORTC1325/KEYNOTE-054 TRIAL MET PRIMARY ENDPOINT OF RECURRENCE-FREE SURVIVAL

* MERCK -SAFETY PROFILE OF KEYTRUDA IN TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES INVOLVING PATIENTS WITH ADVANCED MELANOMA

* MERCK & CO INC - IN ACCORDANCE WITH TRIAL PROTOCOL, STUDY WILL CONTINUE IN ORDER TO EVALUATE OTHER KEY ENDPOINTS, INCLUDING OVERALL SURVIVAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below